vs
Bioceres Crop Solutions Corp.（BIOX）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
Bioceres Crop Solutions Corp.的季度营收约是RE/MAX Holdings, Inc.的1.1倍（$77.6M vs $71.1M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -9.6%，领先11.6%），RE/MAX Holdings, Inc.同比增速更快（-1.8% vs -16.8%），过去两年RE/MAX Holdings, Inc.的营收复合增速更高（-4.7% vs -8.4%）
Bioceres Crop Solutions Corp是一家全球农业科技企业，研发并商业化耐旱种子性状、生物肥料、生物农药等可持续作物增产解决方案，服务南美、北美、欧洲及亚太地区的农户，致力于提升作物产量，同时降低农业生产的环境影响。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
BIOX vs RMAX — 直观对比
营收规模更大
BIOX
是对方的1.1倍
$71.1M
营收增速更快
RMAX
高出15.0%
-16.8%
净利率更高
RMAX
高出11.6%
-9.6%
两年增速更快
RMAX
近两年复合增速
-8.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.6M | $71.1M |
| 净利润 | $-7.4M | $1.4M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 9.3% | 13.1% |
| 净利率 | -9.6% | 2.0% |
| 营收同比 | -16.8% | -1.8% |
| 净利润同比 | -20.2% | -75.2% |
| 每股收益（稀释后） | $-0.12 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOXRMAX
| Q4 25 | — | $71.1M | ||
| Q3 25 | $77.6M | $73.2M | ||
| Q2 25 | — | $72.8M | ||
| Q1 25 | $60.6M | $74.5M | ||
| Q4 24 | $98.8M | $72.5M | ||
| Q3 24 | $93.3M | $78.5M | ||
| Q2 24 | — | $78.5M | ||
| Q1 24 | $84.0M | $78.3M |
净利润BIOXRMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-7.4M | $4.0M | ||
| Q2 25 | — | $4.7M | ||
| Q1 25 | $-1.6M | $-2.0M | ||
| Q4 24 | $605.2K | $5.8M | ||
| Q3 24 | $-6.2M | $966.0K | ||
| Q2 24 | — | $3.7M | ||
| Q1 24 | $9.8M | $-3.4M |
毛利率BIOXRMAX
| Q4 25 | — | — | ||
| Q3 25 | 46.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 39.4% | — | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 40.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 50.8% | — |
营业利润率BIOXRMAX
| Q4 25 | — | 13.1% | ||
| Q3 25 | 9.3% | 25.0% | ||
| Q2 25 | — | 19.3% | ||
| Q1 25 | 1.5% | 7.2% | ||
| Q4 24 | 14.5% | 5.9% | ||
| Q3 24 | 2.5% | 19.4% | ||
| Q2 24 | — | 20.6% | ||
| Q1 24 | 15.7% | 5.8% |
净利率BIOXRMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | -9.6% | 5.4% | ||
| Q2 25 | — | 6.4% | ||
| Q1 25 | -2.6% | -2.6% | ||
| Q4 24 | 0.6% | 8.0% | ||
| Q3 24 | -6.6% | 1.2% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | 11.6% | -4.3% |
每股收益（稀释后）BIOXRMAX
| Q4 25 | — | — | ||
| Q3 25 | $-0.12 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-0.02 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $-0.10 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $0.14 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $288.3M | $452.4M |
| 总资产 | $734.9M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资BIOXRMAX
| Q4 25 | — | $118.7M | ||
| Q3 25 | $15.5M | $107.5M | ||
| Q2 25 | — | $94.3M | ||
| Q1 25 | $38.5M | $89.1M | ||
| Q4 24 | $29.2M | $96.6M | ||
| Q3 24 | $32.3M | $83.8M | ||
| Q2 24 | — | $66.1M | ||
| Q1 24 | $16.4M | $82.1M |
总债务BIOXRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益BIOXRMAX
| Q4 25 | — | $452.4M | ||
| Q3 25 | $288.3M | $448.1M | ||
| Q2 25 | — | $442.4M | ||
| Q1 25 | $345.0M | $433.5M | ||
| Q4 24 | $346.3M | $429.5M | ||
| Q3 24 | $346.0M | $423.1M | ||
| Q2 24 | — | $418.4M | ||
| Q1 24 | $348.5M | $412.0M |
总资产BIOXRMAX
| Q4 25 | — | $582.5M | ||
| Q3 25 | $734.9M | $582.2M | ||
| Q2 25 | — | $574.8M | ||
| Q1 25 | $798.2M | $571.4M | ||
| Q4 24 | $835.2M | $581.6M | ||
| Q3 24 | $827.3M | $578.6M | ||
| Q2 24 | — | $571.4M | ||
| Q1 24 | $836.1M | $566.7M |
负债/权益比BIOXRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | — | $33.5M |
| 自由现金流率自由现金流/营收 | — | 47.1% |
| 资本支出强度资本支出/营收 | — | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | — | $56.8M |
8季度趋势，按日历期对齐
经营现金流BIOXRMAX
| Q4 25 | — | $40.9M | ||
| Q3 25 | $14.4M | $17.7M | ||
| Q2 25 | — | $4.6M | ||
| Q1 25 | $23.3M | $5.7M | ||
| Q4 24 | $-5.4M | $59.7M | ||
| Q3 24 | $5.2M | $17.6M | ||
| Q2 24 | — | $15.9M | ||
| Q1 24 | $-17.4M | $9.4M |
自由现金流BIOXRMAX
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率BIOXRMAX
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度BIOXRMAX
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 3.3% |
现金转化率BIOXRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | -8.85× | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | -1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIOX
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
